cookies on this device, please see our
cookie management page. If you close this message or continue to use this site, you consent
AstraZeneca has again been making the headlines for all the wrong reasons after a US court case over the introduction of a generic competitor to anti-depressant Seroquel went against the company. In the meantime, chief executive David Brennan saw his salary bumped up to £9.1m on the back of performance bonuses dating from 2008. But, despite the sideways drift in its share price, it is still attractive for income seekers.